SCHAUMBURG, Ill., Feb. 25, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Frank Harmon as Executive Vice President, Global Operations. In this newly created role, Mr. Harmon will oversee Sagent's Global Operations including Product Development, R&D, Manufacturing, Supply Chain, Regulatory and Global Alliance Management, with oversight support of Quality Assurance. Mr. Harmon will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our “Triple E” strategy which is focused on accelerating our growth and enhancing our operational performance,” said Mr. Oberman. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation.”
Mr. Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as Vice President, Operations of Nesher Pharmaceuticals (“Nesher”), a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products. Prior to joining Nesher, Mr. Harmon served as Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, where he was responsible for managing a global network of parenteral manufacturing facilities and its global supply chain including supply from some of Sagent’s current partners. He earned an MBA degree from St. Louis University and holds a bachelor's degree in Biology and Chemistry from Western Kentucky University.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605


Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 



